Predictors of response to viscosupplementation in patients with hip osteoarthritis: results of a prospective, observational, multicentre, open-label, pilot study by unknown
RESEARCH ARTICLE Open Access
Predictors of response to
viscosupplementation in patients with
hip osteoarthritis: results of a prospective,
observational, multicentre, open-label,
pilot study
Florent Eymard1*, Bernard Maillet2, Henri Lellouche3, Sylvie Mellac-Ducamp4, Olivier Brocq5, Damien Loeuille6,
Xavier Chevalier1, Thierry Conrozier7 and on behalf of the Osteoarthritis Group of the French Society of
Rheumatology and of the French Research Group in Interventional Rheumatology
Abstract
Background: To identify predictive factors of response to viscosupplementation (VS) in patients with hip
osteoarthritis (HOA).
Methods: Prospective, multicentre, open-label trial, achieved in daily practice conditions. Patients with HOA
were treated with a single intra-articular injection of a cross-linked hyaluronic acid combined with mannitol
(HAnox-M-XL), using imaging guidance. WOMAC pain and function scores and patient global assessment (PGA) were
assessed at baseline and day 90. Improvement, satisfaction and efficacy were self-assessed at day 90.
Hip radiographs at baseline were scored using Kellgren-Lawrence grade and Osteoarthritis Research Society
International (OARSI) score. Associations between clinical and radiological features and response to VS (pain
improvement > 50% at day 90) were assessed in univariate analysis, and then using logistic regression, adjusted for
confounding factors.
Results: The intent-to-treat (ITT) population included 97 patients (57 females, mean age 63). Ninety completed the
follow-up and 80 had full clinical and radiological data. Response to VS was achieved in 47.8% of patients. In univariate
analysis, the only clinical outcome statistically and negatively related to response was PGA at baseline (p = 0.047).
Radiologically, response to VS was negatively correlated with joint space narrowing (JSN) score (JSN < 2 vs. JSN ≥ 2,
p = 0.01) and was related to the patterns of femoral head migration (p = 0.008). In multivariate analysis, only JSN grade
(p = 0.03) remained significantly related to a poor response.
Conclusion: This pilot study, which needs further confirmation by larger scale trials, suggests that radiological features
might be of importance for the decision of VS in patients with HOA.
Trial registration number: ID RCB N°2013-A00165-40. Registered 31 January 2013.
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Background
Osteoarthritis (OA) is the most common form of articu-
lar disease. Its prevalence is increasing and is expected
to grow from 11% in 2006 to 25% by 2030 [1], mainly as
a consequence of aging population. Hip OA (HOA) is
one of the most frequent cause of lower limb OA and is
responsible of a significant impact on multiple dimen-
sions of quality of life, compared with healthy controls
[2]. HOA was also shown to be associated with an in-
creased risk of all-cause and cardiovascular mortality
among older white women [3]. Total hip replacement,
which is often the only one solution to alleviate pain in
advanced stages of the disease, has been responsible of a
dramatic increase of HOA related expenses during the
last decade. In patients with mild to moderate HOA,
and in those who do not accept or have contra-
indication to surgery, pain management includes analge-
sics, non steroidal anti-inflammatory drugs (NSAIDs),
symptomatic slow acting drugs for OA (SYSADOAs),
physiotherapy, rehabilitation, intra-articular (IA) steroid
injections and viscosupplementation (VS).
VS consists in IA injection (s) of a solution of hyalur-
onic acid (HA) and aims to alleviate pain and improve
joint function, likely by restoring the physiological and
rheological homeostasis of OA joints [4, 5]. Recently VS
has been suggested to be the most effective treatment
for symptomatic knee OA, as attested by an effect-size
of 0.63 [6]. Although VS is likely to be effective for the
treatment of mild to moderate HOA, literature data pro-
vide conflicting results, leading experts to conclude that
sufficient evidences are still lacking to recommend VS in
the management of symptomatic HOA [7]. However the
same authors stressed that a careful analysis of literature
shows that most of the negative studies did not respect
adequate number of injections (one injection of cross-
linked HA or 3 weekly injections of non cross-linked
HA) and appropriate indications (mild to moderate
radiological OA). On the contrary, the Italian cohort [8],
including 1906 patients (4002 injections), strongly sug-
gested a long lasting beneficial effect of ultrasound-
guided injections of HA. Based on literature review [9,
10] the major point on which there is overwhelming
agreement among the experts is that VS must not be
recommended in patients with severe HOA awaiting hip
replacement. A retrospective study including 191 pa-
tients with HOA, has shown that only 1 out of 4 patients
waiting for surgery was satisfied with VS. On the con-
trary, those who did not consider surgery in the short
term had a high success rate (66.6%) [10]. This percent-
age was similar to that of patients fulfilling the Minimal
Clinically Important Improvement (MCII) in an un-
controlled trial, performed in patients with mild to
moderate HOA [11]. Anyway prospective randomized
controlled trials as well as studies focusing on
predictive factors of response according to the OA
phenotype remained to be performed [7, 12–16].
The aim of this observational, prospective study, de-
signed by the OA group of the French Society of
Rheumatology, was to investigate, in daily clinical prac-
tice conditions, the clinical, radiological and technical
factors that may, positively or negatively, influence the
response to VS in patients suffering from HOA.
Methods
Regulatory
The study was carried out in compliance with the princi-
ples of Good Clinical Practice (GCP), and the Declaration
of Helsinki concerning medical research in humans and
the country-specific regulations. Before enrollment, pa-
tients were required to sign an informed consent form
and were free to withdraw at any time for any reason. The
patient informed consent form and the protocol, which
complied with the requirements of the International Con-
ference on Harmonisation (ICH), were reviewed and ap-
proved by the French Comité consultatif sur le traitement
de l’information en matière de recherche scientifique
(CCTIRS). It was registered 31 January 2013 under the N°
ID RCB 2013-A00165-40.
Study design
PREVICOX was an observational, prospective, multicen-
tre, study, conducted in 25 centers in France, under the
aegis of the OA section of the French Society of Rheuma-
tology, between November 2013 and March 2015. In-
vestigators were all rheumatologists belonging to the
French Research Group in Interventional Rheumatol-
ogy (Groupe de Recherche en Rhumatologie Interven-
tionnelle Français, GRRIF). All were highly trained in
IA injection techniques.
Patients
Males and females, fulfilling the American College of
Rheumatology criteria for HOA [17] were enrolled if
their hip pain failed to respond to analgesics and/or
NSAIDs or if they were intolerant to these latter, as rec-
ommended by the French Health Autorities. All patients
had standard anteroposterior (AP) pelvic X-rays, and
Lequesne false profile (LFP) of the target hip [18] and/or
MRI examination performed within the previous
6 months (MRI data will be published separately). The
main exclusion criteria were a known hypersensitivity to
HA or mannitol, a contra-indication for an IA procedure
(patients at high risk of hemorrhage or thrombosis, skin
or systemic infection) or VS within the prior 3 months
and/or IA corticosteroid injection within the previous
month in the target hip.
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Treatment
To avoid differences in response rate due to differences
of efficacy related to HA formulations, only one visco-
supplement was allowed. HAnox-M-XL (marketed as
HAppyCross®, LABRHA SAS, Lyon, France) is a visco-
supplement, specifically designed for middle-sized joints,
that combines a high molecular weight, cross-linked so-
dium hyaluronate of non-animal origin (16 g/l) with
mannitol (35 g/l), supplied in a 2.2 ml syringe. Combin-
ation of mannitol to HA might extend the time of con-
tact between HA and the target tissues thanks to its
ability to protect HA against ROS-mediated degradation
[19]. Only one injection of 2.2 ml was performed for
each patient. HANOX-M-XL, kindly provided by the
manufacturer, was injected intra-articularly by trained
rheumatologists or radiologists under fluoroscopy or
ultrasonography guidance, according to the injector
preference.
Data collection
Patients were assessed by the investigator, at baseline
(Day 0) and 12 weeks after the date of injection (Day
90). IA HA injection could be carried out during the
screening visit or within the next 2 weeks according to
the physician and patient schedule.
Clinical features
At inclusion, demographic and anthropometric data
[age, gender, height, weight and body mass index (BMI)]
and medical history (disease duration, analgesics and
NSAIDs consumption, previous IA injections of HA or
corticosteroids) were recorded. Other investigations in-
cluded the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) [20] and patient global
assessment (PGA), on a 11 point (0–10) Likert scale, at
baseline and D90. At D90, patients self-assessed: 1/level
of satisfaction with the treatment (0: not satisfied, 1:
little satisfied, 2: satisfied, 3: very satisfied); 2/treat-
ment efficacy (0: no efficacy, 1: mild efficacy, 2: good
efficacy; 3: very good efficacy); 3/percentage of im-
provement (0, <25%, 26–50%, 51–75%, >75%); 4/vari-
ation in analgesics/NSAIDs consumption (0, <25%,
26–50%, 51–75%, >75%). At the time of injection, the
presence of a synovial fluid effusion was also recorded.
Radiographic features
Radiographs scoring and morphological evaluation were
performed by a single experienced observer (TC). The
Kellgren-Lawrence (KL) grade [21] and the OARSI score
for joint space narrowing (JSN), osteophytes (Ost), sub-
chondral cysts (SC), femoral head flattening (FHF) were
determined with the help of an atlas [22]. For each fea-
ture, the selected score was the highest one obtained
from the two radiological views (AP or LFP). Kappa
value (95% CI) was 0.91 (0.88–0.94) for JSN assessment,
0.79 (0.71–0.87) for Ost, 0.77 (0.67–0.87) and 0.76
(0.68–0.85) for SC [23]. Hips were also classified accord-
ing to the patterns of femoral head migration: superolat-
eral, superomedial/axial, diffuse, posterior according to
Ledingham classification [24]. At last, a morphological
evaluation of architectural abnormalities according to
the description by Lequesne et al. [25] was made: pres-
ence or not of hip dysplasia, femoroacetabular impinge-
ment (FAI) and coxa profunda.
Technical features
The imaging guidance (fluoroscopy or ultrasonography),
as well as the kind (complete or relative) and duration
(in hours) of the recommended rest, were also recorded.
In case of the use of a contrast agent, the amount
injected was notified.
Safety evaluation
Adverse events (AEs) were collected at each visit and
categorized using the Medical Dictionary for Regulatory
Activities (MedDRA). Definition of adverse events and
serious adverse events (SAEs) were in accordance with
the European standard EN ISO 14155: 2011. Investiga-
tors had to note all AEs on the report form. Any AE had
to be assessed by the investigator regarding severity, in-
tensity into “mild, moderate or severe”. In case of SAE,
the investigator was required to declare it immediately
to the sponsor on a specific form to be sent by fax
within 24 h after becoming aware of the event. The
investigator also assessed the causal relationship as
“excluded” or “not excluded” with the treatment and/
or the procedure of IA injection. All AEs whose oc-
currence could not reasonably be attributed to other
causes that the injected treatment, were to be consid-
ered as potential reactions to it and the relationship
was assessed “not excluded”.
Response to treatment
Response to treatment was defined in multiple separ-
ate ways. For reasons that will be discussed below,
“responders” were primarily defined as patients who
experienced an improvement >50%, 90 days after
injection.
“Responders” were secondarily defined as:
1) Patients who were “very satisfied” or “satisfied” with
the treatment.
2) Patients who experienced a decrease in WOMAC
pain score > 50%.
3) Patients whose decrease of pain was greater than the
MCII [26].
4) Patients whose pain at the end of follow-up was
< Patient Acceptable Symptom State (PASS) [27].
Eymard et al. BMC Musculoskeletal Disorders  (2017) 18:3 Page 3 of 8
Statistics
XLSTAT® 2015 software (Addinsoft®, Paris, France) was
used for statistical analysis.
Baseline and 3-month follow-up characteristics are
presented as percentage or median [ranges]. A Mann–
Whitney or a chi-square was used to assess the associ-
ation of quantitative or qualitative factors and response
to treatment. Multivariate logistic regression analysis
was used to identify independent predictors to VS re-
sponse and included sex, age, symptoms at baseline and
other factors with P < 0.20 on univariate analysis. P < 0.05
was considered statistically significant.
Results
Population
One hundred patients were enrolled in PREVICOX
study. The intent-to-treat (ITT) population included 97
patients (3 patients withdrawn from the study before in-
jection) and was constituted of 57 females and 40 males.
Ninety patients completed the study (per protocol popu-
lation). Full clinical and radiographic data were available
in 80 patients (X rays population). No significant differ-
ence in any demographic and clinical items was found
between the 3 populations. Detailed data are summa-
rized in Tables 1 and 2.
JSN was correlated with disease duration (p = 0.009)
but not with age, gender, BMI and WOMAC scores. KL
score was related to disease duration (p = 0.03),
WOMAC total score (p = 0.001) and PGA (p = 0.036)
but not with age, gender, BMI and WOMAC pain score.
There was a significant association between Ost score
and PGA (p = 0.02). Total OARSI score (JSN +Ost + SC)
was correlated to both PGA and disease duration but
not with other items.
Efficacy outcomes
In ITT population, all clinical outcomes decreased sig-
nificantly between baseline and month 3. Detailed data
are shown in Table 3. At baseline 7% of the patients ful-
filled criteria for PASS (26). They were 47% at the end of
follow-up. MCII threshold was reached in 50% of cases.
The decrease of WOMAC pain score was significantly
higher in patients with JSN grade 0, 1 and 2 than in those
with grade 3 (p = 0.003). The same was found when com-
paring JSN grade 0–1 to grade 2–3 (p = 0.01). A similar
trend was found for KL score but did not reach statistical
significance (KL I-II versus III-IV, p = 0.06). The decrease
in WOMAC pain score was also correlated with baseline
WOMAC pain score (p = 0.002), but not with baseline
PGA or WOMAC total score (p = 0.07 and 0.12 respect-
ively). This outcome was highly correlated with satisfac-
tion and efficacy assessment (p < 0.0001).
Response to treatment
To the question “did you experience any improvement
since the time of injection?” 82.2% of patients answered
“yes”. Among them, 14.9% reported an improvement of
less than 25 and 27.0% reported an improvement between
25 and 50%. Only those who reported an improvement
greater than 50% were classified as “responders” (47.8% of
the whole population).
Patient’s self-assessment of improvement was highly
correlated with the decrease of WOMAC pain and total
scores (p < 0.00001), level of satisfaction (p < 0.00001),
patient’s assessment of efficacy (p < 0.00001), MCII
(p < 0.0001) and PASS (p < 0.0001). In the PP population
52 patients were satisfied with the treatment and 38 were
not. However the number of satisfied patients with the
treatment was slightly greater than that of the number of
responders according to our definition (57.8% versus








Gender (Females) 58.8% 56.7% 53.2% >0.05
Age (Years) 63.0 (36.0–87.0) 63.0 (36.0–87.0) 62.0 (36.0–87.0) >0.05
BMI (kg/m2) 25.1 (17.8–41.8) 24.9 (17.8–41.8) 24.9 (17.8–41.8) >0.05
Disease duration (months) 12.0 (1.0–200.0) 12.0 (1.0–200.0) 12.0 (1.0–200.0) >0.05
WOMAC pain 26.0 (7.0–42.0) 25.0 (7.0–42.0) 26.0 (7.0–42.0) >0.05
WOMAC total 120.0 (41.0–194.0) 116.0 (41.0–194.0) 120.0 (41.0–194.0) >0.05
PGA 7.0 (3.0–10.0) 6.0 (3.0–10.0) 6.0 (3.0–10.0) >0.05
Previous hip steroid injection 17.5% 16.7% 20.3% >0.05
Previous hip HA injection 17.5% 17.8% 15.2% >0.05
NSAIDS regular intake 40.0% 42.2% 38.7% >0.05
Analgesics regular intake 63.8% 67.0% 64.5% >0.05
Data are median (range) or percentage of cases. Each WOMAC item was measured on a 11-point Likert scale
ITT: intent-to-treat, PP: per protocol, BMI: body mass index, WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index, PGA: patient global assess-
ment, HA: hyaluronic acid, NSAID: non-steroidal anti-inflammatory drug
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47.8%) showing that the patient’s expectation and feeling
are not exclusively and strictly dependent on the symp-
toms decrease. For instance, it is interesting to mention
that 4 out of 7 (57.1%) of patients with the lowest
WOMAC pain score at baseline (≤15) were not satisfied,
whereas 46 out of 73 (63.0%) with WOMAC pain score
between 16 and 35 at baseline were satisfied with the
treatment.
Predictors of response
In univariate analysis, response to treatment was unre-
lated to gender (p = 0.26), BMI (p = 0.92) disease dur-
ation (p = 0.50), NSAIDS or analgesics consumption at
baseline (p = 0.79 and p = 0.49, respectively), previous
steroid or HA IA injection (p = 0.30 and p = 0.19 re-
spectively), imaging guidance (ultrasonography versus
fluoroscopy, p = 0.60), presence or lack of synovial effu-
sion (p = 0.47), recommendation of rest the day follow-
ing injection (p = 0.48), and occurrence of treatment
related adverse events (p = 0.95). The only clinical data
statistically and negatively related to response to treat-
ment was PGA at baseline (p = 0.047).
Radiologically, the response to treatment was negatively
correlated with JSN score (JSN < 2 mm vs. JSN >
2 mm, p = 0.019) and was related to the patterns of
femoral head migration (p = 0.008). Forty-nine percent
of the patients with supero-lateral JSN were classified as
responders vs. 63% of those with supero-medial and axial
JSN. Only 1 patient out of the 5 with posterior JSN was re-
sponder. No correlation was found between response to
treatment and Ost score (p = 0.74), SC score (p = 0.56)
and OARSI global score (p = 0.28). Correlation between
KL score and response did not reach statistical signifi-
cance (p = 0.18). The percentage of responders was 50% in
patients without architectural abnormality, 40% in patients
with hip dysplasia, 69% in patients with FAI and 62% in
patients with coxa profunda. However, these differences
did not reach statistical significance (p = 0.40).
In multivariate analysis, only JSN grade (p = 0.03)
remained significantly related to response to treatment,
whereas the decrease in WOMAC pain score was corre-
lated to both WOMAC pain score at baseline (p = 0.007)
and JSN (p = 0.01).
Adverse events
Nine adverse events were reported (9.18%). Three were
classified as device/procedure AEs (3.1%). All 3 were de-
scribed as an increase of the hip pain that occurred the
very next hours after injection. Two resolved in less than
Table 2 Radiographic features in X-Rays population
X-Rays population















OARSI grade for SC (N = 78)
0 66
1 12











Data are number of cases
KL: Kellgren-Lawrence, OARSI: OsteoArthritis Research Society International,
JSN: joint space narrowing, Ost: osteophytes, SC: subchondral cyst
Table 3 Clinical assessment at baseline and 90 days after viscosupplementation
Baseline Day 90 Baseline vs. Day 90
P value
WOMAC Pain 26.0 (7.0–42.0) 16.5 (0.0–46.0) <0.0001
WOMAC Stiffness 10.0 (0.0–18.0) 6.0 (0.0–17.0) <0.0001
WOMAC Function 84.0 (23.0–134.0) 58.0 (0.0–133.0) <0.0001
PGA 7.0 (3.0–10.0) 5.0 (0.0–10.0) <0.0001
Data are median (range) or percentage of cases. Each WOMAC item was measured on a 11-point Likert scale
PGA, patient global assessment
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24 h with rest and paracetamol. One resolved in 1 week
and needed NSAIDs. The other AES were low back pain
(2 cases), sciatica (1 case), knee pain in patient with knee
OA (1 case) and dizziness (1 case) and were considered
as unrelated to the treatment and/or the procedure of
injection. One patient, with a very high level of pain at
baseline (WOMAC pain = 39/50, PGA = 9/10) under-
went total hip arthroplasty during the follow-up.
Discussion
This pilot study, aimed to identify predictive factors of
response of a single IA injection of HAnox-M-XL in pa-
tients with hip OA, has chiefly highlighted the role of
OA severity as a predictor of efficacy. More than the KL
grade, which is a composite index taking into account
both JSN and osteophyte, it seems that it is the severity
of JSN is the best predictor of response to treatment. In
our study, patients with a JSN graded OARSI 2 and 3
had a lower rate of success as compared to patients with
grade 0 and 1. This has already been suggested in a pre-
vious clinical trial [28].
Moreover, the impact of OA severity on VS failure has
been confirmed for the knee joint by the meta-analysis
published by Wang et al. [29] and by the recent analysis
from the FLEXX database [30]. Moreover, this finding is
consistent with the results of a previous study including
knee OA patients and showing an inverse relation be-
tween VS effectiveness and initial levels of several cata-
bolic biomarkers measured in synovial fluid reflecting
OA severity [31]. Literature data do not provide robust
data to explain the association between OA severity and
VS response. However, previous in vivo and in vitro
studies highlighted the anti-inflammatory and pro-
anabolic effects of exogenous HA on different joint
tissues such as synovium and cartilage, which may
contribute to the symptom improvement following VS
[32]. However, in case of severe OA lesions, inflam-
matory and pro-catabolic profile of cartilage and syno-
vium are substantial and so, we may assume that HA
properties wont be enough to counteract the deleterious
profile of OA tissues. Moreover, in OA joints, the decrease
in molecular weight and concentration of HA leads to re-
duced rheological properties of synovial fluid, which can
be partly restore by exogenous HA. But, we can suppose
that VS is less efficient when rheologic properties are
deeply altered as in severe OA.
Likewise, patients with high WOMAC pain score and
PGA score at baseline are likely to have a poorer result
than those with medium pain level. Interestingly, pa-
tients with low level of pain at baseline had less success-
ful results than those with moderate pain. The most
likely hypothesis is that those patients were expecting a
complete disappearance of symptoms they did not ob-
tain. Consequently, it seems that patients should have
sufficient pain level before treatment in order to perceive
improvement as significant.
The other trend that emerges from this study is the
role of patterns of femoral head migration. Patients with
superomedial and axial JSN are likely to be improved
than those with superolateral or posterior JSN. This ob-
servation was not confirmed in multivariate analysis
probably because of a lack of statistical power related to
the too small number of patients. Likewise, despite the
lack of statistical significance, the study suggests that the
best results are obtained in patients with coxa profunda
and FAI, resulting mostly in a superomedial axial JSN.
Furthermore patients with hip dysplasia (i.e. with super-
olateral narrowing) had a lowest rate of success than
those with coxa profunda and FAI or without architec-
tural abnormality.
Another interesting point to underline is the absence
of influence of the BMI on clinical results. Even in pa-
tients with BMI > 30 there was no trend for a poorer ef-
ficacy of VS. This confirms that hip and knee OA are
two very different entities both in terms of patient pro-
file and in terms of treatments efficacy. Similarly, gender
and age are not associated with treatment response and
patients satisfaction. More interesting is the lack of in-
fluence on response of rest after injection. However the
very large majority of physicians advised a relative rest
for 24 h and the number of patients who were not ad-
vised to have rest is probably too small for showing a
statistical difference, if there is one.
The relatively small number of patients is the main limi-
tation of the study. Another one is due to the absence of
some radiographic views such as the Dunn view allowing
a better evaluation of FAI, particularly for diagnosis of
cam-type FAI [33], which may have been underestimated.
Conclusion
Despite some limitations this prospective study, per-
formed in daily practice conditions, demonstrated that VS
with HAnox-M-XL alleviate pain by 50% or more in more
than half of patients with hip OA. The best success rate
was obtained in patients with mild to moderate JSN, those
with moderate pain and disability, and in case of supero-
medial and axial femoral head migration. This study also
suggested that better results are obtained in FAI and coxa
profunda than in hip dysplasia. Based on these results it is
now possible to design a placebo-controlled trial to deter-
mine the real efficacy of hip joint VS.
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